Journal
NATURE
Volume 551, Issue 7679, Pages 247-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nature24297
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) of the National Institutes of Health (NIH) (Cancer Target Discovery and Development Network) [U01CA168370, U01CA217882, U01CA176152, U01CA168397, R01CA212767]
- Susan G. Komen for Cure Postdoctoral Fellowship [KG1101214]
- Howard Hughes Medical Institute
Ask authors/readers for more resources
Acquired drug resistance prevents cancer therapies from achieving stable and complete responses(1). Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer 'persister' cells(2-4). The persister cell pool constitutes a reservoir from which drug-resistant tumours may emerge. Targeting persister cells therefore presents a therapeutic opportunity to impede tumour relapse(5). We previously found that cancer cells in a high mesenchymal therapy-resistant cell state are dependent on the lipid hydroperoxidase GPX4 for survival(6). Here we show that a similar therapy-resistant cell state underlies the behaviour of persister cells derived from a wide range of cancers and drug treatments. Consequently, we demonstrate that persister cells acquire a dependency on GPX4. Loss of GPX4 function results in selective persister cell ferroptotic death in vitro and prevents tumour relapse in mice. These findings suggest that targeting of GPX4 may represent a therapeutic strategy to prevent acquired drug resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available